Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- 2010 ESC Congress Held in Stockholm
September 13, 2010
- Ono Licenses Salirasib from Concordia
September 13, 2010
- BI Applies for Dabigatran for SPAF in Japan
September 13, 2010
- ViiV Starts Full-Scale Operations in HIV Area in Japan
September 13, 2010
- Daiichi Sankyo Confident About Differentiation of Edoxaban
September 13, 2010
- Novartis Enhances Supply of Scientific Information
September 13, 2010
- Eisai's PAR-1 Antagonist Appears Promising as New Drug for Atherothrombosis
September 13, 2010
- Takeda Licenses Cell Culture-Based Flu Vaccine Technology from Baxter
September 13, 2010
- Astellas Confirms YM150's Safety for AF in PIIa in Japan/Asia
September 13, 2010
- Takeda Completes Computerization in Synthetic Study Dept.
September 13, 2010
- MSD to Enter PIII for Betrixaban in 2011
September 13, 2010
- RaQualia Licenses Acid Pump Antagonists to CJ Cheil Jedang
September 13, 2010
- Genetic Variability Does Not Affect Responses to Ticagrelor: PLATO Study Subanalysis
September 13, 2010
- Novartis Makes Alcon Consolidated Subsidiary
September 13, 2010
- Towa to Expand Production Capacity with New Plant
September 6, 2010
- JCMOA to Be Kicked Off in October
September 6, 2010
- Banyu Files an NDA for Daptomycin
September 6, 2010
- Perampanel Shows Efficacy for Refractory Partial Seizure in PIII: Eisai
September 6, 2010
- Diovan Becomes Best-Selling Drug in April-June: IMS Japan
September 6, 2010
- Homeopathy Has No Scientific Grounds: SCJ
September 6, 2010
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…